article thumbnail

Researchers map how the brain regulates emotions

Science Daily: Pharmacology News

A new study is among the first of its kind to separate activity relating to emotion generation from emotion regulation in the human brain. The findings provide new insights that could help inform therapeutic treatments regarding mental health and drug addiction.

article thumbnail

An astrocytic pH regulator that can repair the blood-brain barrier and reverse brain damage caused by ischemic stroke

Science Daily: Pharmacology News

A recent study has found that an ion transporter protein that regulates the pH of specific brain cells can repair the blood-brain barrier and restore normal brain function after ischemic stroke.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Regulator and Funder? FDA’s Orphan Products Grants Program awards significant funding to help move promising treatments through clinical development

FDA Law Blog: Drug Discovery

Food and Drug Administration (FDA) plays a pivotal role in fostering the development of treatments for rare diseases through its Orphan Products Grants Program. The Natural History Studies Grants Program funds natural history studies that collect gather data on how rare diseases progress over time without treatment.

article thumbnail

FDA sets decision dates for Vertex, CRISPR gene editing drug

BioPharma Drive: Drug Pricing

The regulator will issue separate verdicts on the pioneering treatment’s use in sickle cell disease and beta thalassemia, with the first expected late this year.

FDA 328
article thumbnail

Tau-regulating protein identified as a promising target for developing Alzheimer's disease treatment

Science Daily: Pharmacology News

A gene encoding a protein linked to tau production -- tripartite motif protein 11 (TRIM11) -- was found to suppress deterioration in small animal models of neurodegenerative diseases similar to Alzheimer's disease (AD), while improving cognitive and motor abilities, according to new research.

Disease 189
article thumbnail

European regulators push Biogen, CRISPR drugs toward approval

BioPharma Drive: Drug Pricing

While a positive recommendation for the gene editing treatment Casgevy was expected, a clearance for Biogen’s Skyclaris, acquired through a recent acquisition, was no sure bet.

article thumbnail

Bluebird, playing catch-up, gets decision date for sickle cell gene therapy

BioPharma Drive: Drug Pricing

The regulator will issue a decision on lovo-cel by Dec. 20, roughly two weeks after a verdict is expected on a rival gene editing treatment from Vertex and CRISPR Therapeutics.

Therapies 258